Background
==========

During the past decade, microarray-based gene expression analysis gave rise to a large number of candidate genes for the diagnostics and therapy of cancer. Bioinformatic approaches delivered gene sets, the expression patterns of which were predictive for certain cancer phenotypes. A synergy between these advances and the development of screening tools for a rapid and reliable screening of marker gene expression represents an important step towards an improved treatment of cancer.

Methods
=======

For the semiquantitative expression screening of 11 candidate genes for drug resistance in melanoma, we combined multiplex RT-PCR (mRT-PCR) with subsequent microfluidic fragment analysis.

Results
=======

The functionality of this approach was demonstrated by low interexperimental variations of amplicon quantities after endpoint analysis. Applied to RNA samples derived from drug-sensitive and drug-resistant melanoma cell lines, mRT-PCR delivered results qualitatively concordant with data obtained from northern blot analyses and array analyses. A preliminary screen of four additional melanoma cell lines points to *IL1B*, *APOD,*and *CYR61*as interesting candidates for drug-resistance associated genes. First tests using an automated on-chip electrophoresis platform indicate the applicability of this approach for high-throughput measurements.

Conclusion
==========

mRT-PCR combined with on-chip electrophoresis reveals a rapid and easy-to-handle method for candidate gene set evaluation from limited amounts of mRNA. Using gene sets indicative for different tumor phenotypes, this procedure may represent an alternative for future cancer diagnostics.
